Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Asset Tracing & Recovery

What are the main procedural steps in OFAC sanctions intersection with Russian asset recovery strategy in the pharmaceuticals sector?

Elizaveta Razina · June 2026 · 3 min read

OFAC and Russian constraints complicate pharmaceutical asset recovery in Russia. Russian-law steps remain within compliance limits. Make an enquiry.

When a foreign creditor's Russian asset recovery strategy in the pharmaceuticals sector intersects with OFAC sanctions, the operative question is not whether an OFAC licence removes all constraints, but which Russian-law procedural steps remain available within the compliance envelope established by US counsel.

The short answer is that Russian civil procedure, insolvency law, and interim relief mechanisms operate independently of OFAC's administrative framework. OFAC designations may block the transfer of funds or assets to or from a sanctioned party under US jurisdiction, but they do not suspend Russian court proceedings, eliminate a creditor's right to file a claim, or extinguish a pledge or security interest under Russian law. The two regimes run in parallel and must be managed in parallel.

In practice, the principal Russian-law procedural steps that remain available — and that foreign pharmaceutical creditors frequently overlook while awaiting OFAC licence determinations — are: first, preserving limitation periods by filing a claim in the relevant Russian arbitrazh court before the Russian statutory period expires, independent of OFAC status; second, registering any security interest or pledge with the relevant Russian registry to protect priority against competing creditors; third, applying for interim asset preservation measures (обеспечительные меры) from the arbitrazh court, which can freeze Russian-domiciled assets without requiring any transfer of value and therefore without triggering OFAC transfer prohibitions; and fourth, filing a creditor's claim in any insolvency proceeding the Russian counterparty may initiate, since failure to file within the statutory window permanently extinguishes priority. In pharmaceutical sector matters specifically, regulatory licences, product registration certificates, and intellectual property held by the Russian counterparty may constitute recoverable assets under Russian law that are not themselves directly within OFAC's scope.

The practical risk for foreign creditors is that OFAC licence processing timelines — which may extend well beyond 12 months for complex general licences — can cause Russian limitation periods to lapse if no protective steps are taken in Russian courts in the meantime.

For advice on coordinating OFAC compliance with a live Russian asset recovery strategy in the pharmaceuticals sector, see also OFAC Sanctions Intersection with Russian Asset Recovery Strategy — Practice Briefing and the Asset Tracing & Recovery practice page. For the Russian-law dimension of asset recovery more broadly, see What are the main procedural steps in Russian asset recovery?.

If your Russian pharmaceutical counterparty holds recoverable assets and OFAC compliance is complicating your recovery timeline — make an enquiry: info@vetrovpartners.com |

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry